AUSTRALIAN PRODUCT INFORMATION – COMIRNATY …
2. QUALITATIVE AND QUANTITATIVE COMPOSITION This is a multidose vial and must be diluted before use. One vial (0.45 mL) contains 6 doses of 0.3 mL after dilution, see Sections 4.2 and 6.6. 1 dose (0.3 mL) contains 30 micrograms of …
Tags:
Information, Product, Quantitative, Product information, Dilution
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
AUSTRALIAN PRODUCT INFORMATION (ChAdOx1-S) …
www.tga.gov.auAUSTRALIAN PRODUCT INFORMATION COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection . 1 NAME OF THE MEDICINE . ChAdOx1-S (provisional ABN) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION . Each multi-dose vial contains 5x10. 11. viral particles (vp) of (ChAdOx1-S . a, b) in 5 mL. One dose (0.5 mL) contains 5x10. 10. vp of …
Information, Product, Name, Product information, Qualitative, Astrazeneca
COMIRNATY™ COVID-19 VACCINE
www.tga.gov.auDo not receive this vaccine if you are allergic to any of these ingredients. What COMIRNATY looks like COMIRNATY is a white to off-white suspension provided in a multidose clear glass vial. After dilution, each vial contains 6 doses of vaccine. AUST R 346290. Who distributes COMIRNATY Pfizer Australia Pty Ltd Sydney NSW www.pfizer.com.au
Guideline for the labelling of medicines
www.tga.gov.auGuideline for the labelling medicines of istorical consultation document Draft - Version 1.0, August 2014
Australian public assessment report for Linagliptin
www.tga.gov.au• An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission.
Assessment, Report, Public, Australian, Public assessment, Australian public assessment report for linagliptin, Linagliptin
Australian Public Assessment Report for Silodosin
www.tga.gov.auAustralian Public Assessment Report for Silodosin Proprietary Product Name: Urorec ... • To report a problem with a medicine or medical device, please see the information on ... //www.tga.gov.au>. About AusPARs • An Australian Public Assessment Re port (AusPAR) provides information about the evaluation of a prescription medicine and the ...
Assessment, Report, Public, Australian, Ports, Australian public assessment report for silodosin, Silodosin, Public assessment re port
Guidance 18: Impurities in drug substances and …
www.tga.gov.auTherapeutic Goods Administration Guidance 18: Impurities in drug substances and drug products V1.0 August 2013 Page 3 of 13 Version history Version Description of change Author Effective date
Drug, Impurities, Substance, Impurities in drug substances and, Impurities in drug substances and drug
Explanatory notes for pharmaceutical manufacturers on the ...
www.tga.gov.auPE 008-4 3 of 8 1 January 2011 4. SCOPE These Explanatory Notes apply to the preparation and content of the Site Master File. Manufacturers should refer to regional / …
Notes, Pharmaceutical, Life, Manufacturers, Explanatory notes, Explanatory, Explanatory notes for pharmaceutical manufacturers
The use of GMDN codes for IVD medical devices in Australia
www.tga.gov.auGlobal Medical Device Nomenclature (GMDN) The GMDN is an international nomenclature system used by regional or national regulatory bodies to consistently describe medical devices: 1 • consistent assessment of devices before they are approved for supply . GMDN codes are used to
Devices, Medical, Global, Nomenclature, Global medical device nomenclature
COVID-19 rapid antigen self-tests
www.tga.gov.auCOVID-19 rapid antigen self-tests. This guidance refe rs to COVID -19 (caused by SARS-CoV-2) only and does not include self-tests to detect other types of coronavirus , or COVID_19 rapid antibody tests . COVID-19 rapid antigen self-tests are tests that allow individuals to collect a specimen, conduct a test and interpret the results by themselves.
Australian public assessment report for BNT162b2 (mRNA)
www.tga.gov.auThe RNA is encapsulated in lipid nanoparticles (LNPs), which enables entry into host cells, expression of the S protein, and elicitation of both antibody and cellular immune responses. The vaccine is supplied as a white to off white sterile frozen liquid, packaged in a multi dose clear glass 2 mL vial with a rubber stopper,
Related documents
Real-time PCR handbook - Faculdade de Filosofia, Ciências ...
www.ffclrp.usp.brquantitative PCR (often shortened to real-time PCR or qPCR), PCR product is measured at each cycle. ... cloning, and use in other molecular biology techniques. In real-time PCR, the amount of DNA is measured after ... The samples used to create the plots in this fi gure are a dilution series of the target DNA sequence. NTC, no-template control. 2
Real-time PCR handbook - Gene-Quantification
www.gene-quantification.detime quantitative PCR was developed and end-point PCR is used mostly to amplify specific DNA for sequencing, cloning, and use in other molecular biology techniques. In real-time PCR, the amount of DNA is measured after each cycle via fluorescent dyes that yield increasing fluorescent signal in direct proportion to the number
Australian Product Information - Comirnaty (BNT162b2 …
www.tga.gov.au2. QUALITATIVE AND QUANTITATIVE COMPOSITION This is a multidose vial and must be diluted before use. One vial (0.45 mL) contains 6 doses of 0.3 mL after dilution, see Sections 4.2 and 6.6. 1 dose (0.3 mL) contains 30 micrograms of …
REG 174 INFORMATION FOR UK HEALTHCARE …
assets.publishing.service.gov.ukdilution date and time and stored between 2°C to 25°C. Use as soon as practically possible, and within 6 hours after dilution. After dilution, the vial contains 6 doses of 0.3 mL. Withdraw the required 0.3 mL dose of diluted vaccine using a sterile needle and syringe and administer. Low dead-volume syringes and/or needles
Sensitivity, Background, Noise, and Calibration in Atomic ...
resources.perkinelmer.comdilution factor and matrix effects. For example, if 1 g of sample is dissolved and brought to a final volume of 100 mL, the detection limit in the solution must be multiplied by the dilution factor (100x in this example) to know what level of analyte in the original solid sample could have been measured if it could have been analyzed directly.
Sensitivity, Calibration, Background, Noise, Dilution, Calibration and
‘Taking the Risk out of Allergen Risk Assessment ...
www.ifst.orgsemi-quantitative (or, in exceptional circumstances, quantitative) estimation of whether a hazard is likely to occur in practice; normally expressed as a risk factor or score by multiplying the hazard severity score by a likelihood score (unlikely [score 1], …